Abstract
Human plasmacytoid dendritic cells (pDC) are crucial for the modulation of adaptive immune responses in the course of neoplastic, viral and autoimmune diseases. In several of these disorders deregulated pDC-derived interferon-α (IFN-α), a key cytokine produced by pDC, plays a central role. Apart from IFN-α, pDC can produce a variety of other mediators, which are involved in immunological cross-talk. The most recently discovered are the cytotoxic serine protease granzyme B (GrB) and indoleamine 2,3-dioxygenase, which have been described to be involved in the suppression of effector T cell responses. Here we review the regulation of pDC function by a variety of immunomodulatory agents, which may be developed as future candidates for the therapy of a variety of diseases. Moreover, we introduce the novel concept of enhancing immune responses after vaccination in poor responders by increasing pDC-derived IFN-α and simultaneously inhibiting pDC-derived GrB secretion. Finally we discuss potential approaches to abrogate pDC-mediated tolerance induction against tumors and viral infections.
Keywords: pDC, IFN-α, TNF-α, granzyme B, TRAIL, IDO, HMGB1, IL-6, IL-12, IP-10, Interleukin, Vasoactive intestinal peptide
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Volume: 11 Issue: 2
Author(s): Dorit Fabricius and Bernd Jahrsdorfer
Affiliation:
Keywords: pDC, IFN-α, TNF-α, granzyme B, TRAIL, IDO, HMGB1, IL-6, IL-12, IP-10, Interleukin, Vasoactive intestinal peptide
Abstract: Human plasmacytoid dendritic cells (pDC) are crucial for the modulation of adaptive immune responses in the course of neoplastic, viral and autoimmune diseases. In several of these disorders deregulated pDC-derived interferon-α (IFN-α), a key cytokine produced by pDC, plays a central role. Apart from IFN-α, pDC can produce a variety of other mediators, which are involved in immunological cross-talk. The most recently discovered are the cytotoxic serine protease granzyme B (GrB) and indoleamine 2,3-dioxygenase, which have been described to be involved in the suppression of effector T cell responses. Here we review the regulation of pDC function by a variety of immunomodulatory agents, which may be developed as future candidates for the therapy of a variety of diseases. Moreover, we introduce the novel concept of enhancing immune responses after vaccination in poor responders by increasing pDC-derived IFN-α and simultaneously inhibiting pDC-derived GrB secretion. Finally we discuss potential approaches to abrogate pDC-mediated tolerance induction against tumors and viral infections.
Export Options
About this article
Cite this article as:
Fabricius Dorit and Jahrsdorfer Bernd, Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187153011795564205
DOI https://dx.doi.org/10.2174/187153011795564205 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies
Current Vascular Pharmacology Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Synthetic Peptides for the Immunodiagnosis of Human Diseases
Current Medicinal Chemistry Is Autoimmunity a Component of Natural Immunity to HIV?
Current HIV Research Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry Phosphoinositide 3-Kinase Gamma (PI3Kγ) Inhibitors for the Treatment of Inflammation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design A Quantitative Structure-Activity Relationship Study on Some Series of Potassium Channel Blockers
Medicinal Chemistry DNA Vaccines: A Mini Review
Recent Patents on DNA & Gene Sequences Oral Contraceptives and Autoimmune Diseases
Current Women`s Health Reviews Synthetic Peptides in the Diagnosis of Systemic Autoimmune Diseases
Current Protein & Peptide Science Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy Interactions of Sex Steroids with Mechanisms of Inflammation
Current Drug Targets - Inflammation & Allergy Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design